tiprankstipranks
Altimmune (ALT)
NASDAQ:ALT
US Market
Want to see ALT full AI Analyst Report?

Altimmune (ALT) Blogger Opinions & Sentiment

3,678 Followers

Blogger Sentiment

Bullish: 80.00%
Sector Average
Bullish
ALT Blogger sentiment is based on 5 Blogger Opinions. The Blogger sentiment is more Bullish than other stocks in the Healthcare sector.

Blogger Article Distribution

ArticleDistribution
40% SeekingAlpha
40% Zacks
20% GuruFocus
The distribution of articles among the main online Financial Blogging platforms.

Top Blogger Bearish Predictions

Not enough top blogger opinions at this time
Please return soon. This page is being updated.
Recent negative articles by top bloggers.

Top Blogger Bullish Predictions

Here's Why You Should Add Altimmune Stock to Your Portfolio Now
Zacks
Altimmune (ALT) Gains Buy Rating with Promising MASH Treatment
GuruFocus
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
Zacks
Recent positive articles by top bloggers.

Financial Blogger Predictions​​

Blogger Performance
Any
Any
Blogger Sentiment
Any
Any

FAQ

What do Seeking Alpha bloggers think of ALT?
Seeking Alpha’s Biotech Beast has a Neutral Sentiment.
    What do Motley Fool contributors think of ALT?
    Currently there's no blogger sentiment for ALT.
    What Is ALT’s Blogger Sentiment?
    ALT’s Blogger Sentiment is Bullish.
      What was the most recent blogger prediction for ALT?
      The most recent blogger prediction for ALT was made by Zacks Equity Research, who was Bullish on the stock.
        How can I follow the stock ratings of top Top Financial Bloggers?
        Head over to our Expert Center to see a list of the Top 100 Financial Bloggers and follow the financial bloggers of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Stocks with the Highest Top Blogger Ratings in the Healthcare sector
          SPHRFStarpharma Holdings Limited
          PRRUFImmutep Ltd
          NURPFNeuren Pharmaceuticals Limited
          CLVLFClinuvel Pharmaceuticals